Miragen Therapeutics (MGEN) Short Interest Ratio & Short Volume

Short interest is the volume of Miragen Therapeutics shares that have been sold short but have not yet been closed out or covered. As of December 31st, traders have sold 133,800 shares of MGEN short. 4.85% of Miragen Therapeutics' shares are currently sold short. Learn More on Miragen Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.85% of Miragen Therapeutics' floating shares are currently sold short.

Miragen Therapeutics saw a drop in short interest in the month of December. As of December 31st, there was short interest totaling 133,800 shares, a drop of 17.3% from the previous total of 161,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Miragen Therapeutics currently has issued a total of 3,908,000 shares. Some of Miragen Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Miragen Therapeutics currently has a public float of 2,760,000 shares.

4.85% of Miragen Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Miragen Therapeutics: Enzo Biochem, Inc. (1.90%), Personalis, Inc. (3.03%), Exagen Inc. (0.05%), DermTech, Inc. (10.13%), Biodesix, Inc. (0.30%), CalciMedica, Inc. (0.93%), Aligos Therapeutics, Inc. (1.11%), Annovis Bio, Inc. (14.62%), Immix Biopharma, Inc. (2.80%), Reneo Pharmaceuticals, Inc. (13.80%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($6.95 billion), Aon plc ($4.44 billion), Analog Devices, Inc. ($4.13 billion), Snap Inc. ($3.12 billion), Peloton Interactive, Inc. ($2.68 billion), Moderna, Inc. ($2.60 billion), The Clorox Company ($2.47 billion), The Kroger Co. ($2.32 billion), International Flavors & Fragrances Inc. ($2.21 billion), and Altice USA, Inc. ($1.94 billion). View all of the most shorted stocks.

Short selling MGEN is an investing strategy that aims to generate trading profit from Miragen Therapeutics as its price is falling. MGEN shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Miragen Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of MGEN, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MGEN, twice per month. The most recent reporting period available is December, 31 2020.